Clarity Pharmaceuticals Reaches Milestone in Phase III AMPLIFY Trial for Prostate Cancer Imaging Clarity Pharmaceuticals has successfully achieved its target participant enrollment for the Phase III AMPLIFY trial, aiming to enhance prostate cancer imaging and diagnostics.

Clarity Pharmaceuticals Reaches Milestone in Phase III AMPLIFY Trial for Prostate Cancer Imaging #Australia #Sydney #Prostate_Cancer #Clarity_Pharmaceuticals #AMPLIFY_trial

Clarity Pharmaceuticals Launches Phase III AMPLIFY Trial for Prostate Cancer Recurrence Detection Clarity Pharmaceuticals has initiated the AMPLIFY trial to evaluate the efficacy of 64Cu-SAR-bisPSMA imaging in prostate cancer recurrences, enhancing detection methods.

Clarity Pharmaceuticals Launches Phase III AMPLIFY Trial for Prostate Cancer Recurrence Detection #Australia #Omaha #Prostate_Cancer #Clarity_Pharmaceuticals #AMPLIFY_trial